CSL Limited Annual Report 2021/22 18 Our Value Creation Chain CSL People & Culture Patients and Public Health Strategic Sustainability Pillars & Focus Areas Environment Social Workforce CSL’s Strategy Value we create Our expertise and operations Sourcing including plasma collection Pharmacovigilance CSL’s Purpose, Values and Code of Responsible Business Practice Early stage research & collaboration Product development & clinical trials Manufacturing & distribution Sales, marketing, policy advocacy & patient support What we depend on Unmet need Opportunities to improve and protect the quality of life of patients and communities in therapy areas we treat. Natural resources Includes: plasma donations for rare and serious diseases; influenza virus strains for product manufacture; and environmental inputs such as water and energy. Physical assets Plasma centres to collect rawmaterial, manufacturing facilities for our products, warehouses, offices for our people and laboratories for our scientists. Our people 30,000+ people with diverse skills that are driven by our purpose and values. Financial resources Cash, equity and debt for future growth. Collaborators and business partners Accessing and sharing intellectual know how to develop and innovate our products. A healthier more productive society Protecting global health and the wellbeing of individuals, families, businesses and communities from life-threatening and/or complications resulting from influenza. Saving and/or improving the quality of life of hundreds and thousands of people with rare and serious diseases. Sustainable financial growth Delivering consistent, profitable and responsible growth for our investors, which fuels innovation and development. Social and economic opportunity Enabling hundreds of thousands of people to benefit from opportunity created by growing along with us, including employees, suppliers, plasma donors and research partners. Our promise to patients 3 Our Performance and Strategy
RkJQdWJsaXNoZXIy MjE2NDg3